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Background:	Multimodal	 enhanced	 recovery	 after	 surgery	 (ERAS)	 regimens	 have	33 
improved	outcomes	from	colorectal	surgery.		34 
Objective:	 We	 report	 the	 application	 of	 ERAS	 to	 patients	 undergoing	 radical	35 
cystectomy	(RC).	36 
Design,	 Setting	 and	 Participants:	 Prospective	 collection	 of	 outcomes	 from	37 
consecutive	patients	undergoing	RC	at	a	single	institution.	38 
Intervention:	Twenty-six	components	including	prehabilitation	exercise,	same	day	39 
admission,	 carbohydrate	 fluid	 loading,	 targeted	 intra-operative	 fluid	 resuscitation,	40 
regional	 local	 anesthesia,	 cessation	 of	 NG	 tubes,	 omitting	 oral	 bowel	 preparation,	41 
avoiding	drain	use,	early	mobilization,	chewing	gum	use	and	audit.	42 
Outcome	Measurements	and	Statistical	Analysis:	Primary	outcomes	were	length	43 
of	 stay	 and	 readmission	 rate.	 Secondary	 outcomes	 included	 intra-operative	 blood	44 
loss,	transfusion	rates,	survival	and	histopathological	findings.		45 
Results	 and	 Limitations:	 453	 consecutive	 patients	 underwent	 RC,	 including	 393	46 
(87%)	with	 ERAS.	 Length	 of	 stay	was	 shorter	with	 ERAS	 (median	 (IQR):	 8	 (6-13)	47 
days)	than	without	(18	(13-25),	p<0.001).	Patients	with	ERAS	had	lower	blood	loss	48 
(ERAS:	600	(383-969)	mls	vs.	1050	(900-1575)	mls	for	non-ERAS,		p<0.001),	lower	49 
transfusion	 rates	 (ERAS:	 8.1%	 vs.	 25%,	 Chi	 sq.	 p<0.001)	 and	 fewer	 readmissions	50 
(ERAS:	 15%	 vs.	 25%,	 Chi	 sq.	 p=0.04)	 than	 those	 without.	 Histopathological	51 
parameters	(e.g.	tumor	stage,	node	count	and	margin	state)	and	survival	outcomes	52 






blood	 loss	and	faster	discharge	 for	patients	undergoing	RC.	These	changes	did	not	56 
increase	readmission	rates	or	alter	oncological	outcomes.		57 
Patient	summary:	Recovery	after	major	bladder	surgery	can	be	improved	by	using	58 








Radical	 cystectomy	 (RC)	 with	 pelvic	 lymph	 node	 dissection	 (PLND)	 is	 the	 gold	 standard	64 
treatment	 for	 muscle	 invasive	 BC	 [1],	 plays	 a	 key	 role	 in	 managing	 local	 failure	 after	65 
radiotherapy	 [2]	 and	 is	 an	 option	 for	 high	 risk	 local	 non-muscle	 invasive	 BC	 [3].	 RC	 is	 a	66 
morbid	procedure	that	often	performed	in	older	patients	with	co-existing	cardiopulmonary	67 





In	 colorectal	 surgery,	 the	 use	 of	 multimodal	 Enhanced	 Recovery	 after	 Surgery	 (ERAS)	73 
regimens	has	reduced	post-operative	morbidity	and	length	of	stay	[8,	9].	ERAS	introduces	a	74 
number	of	pre-,	peri-	and	post-operative	steps	to	improve	the	patient	pathway	[10].	Many	75 
ERAS	components	are	generic	 to	abdominal	surgery	and	so	have	been	 implemented	 in	RC	76 














Consecutive	 patients	 undergoing	 RC	 and	 urinary	 reconstruction	 were	 enrolled	 in	 a	88 
prospective	 institutional	database.	From	February	2007	to	October	2016,	a	25	point	ERAS	89 
regimen	was	implemented.	The	regimen	(table	1)	was	derived	from	available	evidence	and	90 
practice	within	 colorectal	 surgery	[10].	Data	were	 collected	prospectively	and	all	patients	91 
undergoing	RC	were	 included	 in	 the	study.	The	use	of	ERAS	 reflected	 the	date	of	surgery.	92 
During	the	transition	period,	patients	were	identified	as	using	the	ERAS	pathway	if	they	had	93 
pre-operative	 carbohydrate	 loading,	 were	 allowed	 fluids	 until	 2	 hours	 prior	 to	 surgery,	94 





cancer	nurse	specialist,	 an	anaesthetist	 (RG)	when	needed,	 and	a	 stoma	 therapist.	Typical	100 
consultations	 included	 wide	 ranging	 treatment	 discussions	 and	 lasted	 30-45	 minutes.	101 
Patients	were	advised	 to	maintain	a	normal	diet	until	 the	night	before	 surgery,	 to	 reduce	102 
cigarette	smoking	and	alcohol	intake,	and	were	given	an	information	booklet	regarding	their	103 
expected	 recovery.	 Increasing	 exercise	 activity	 (prehabilitation)	 was	 stressed	 as	 an	104 
important	 aspect	 of	 recovery	 and	 patients	 asked	 to	walk	 1	 hour	 per	 day	 (once	 or	 twice)	105 
between	 their	 initial	 consultation	 and	 surgery.	 Patients	 whose	 anaesthetic	 fitness	 was	106 
uncertain	were	reviewed	by	an	Anaesthetist	and	cardiopulmonary	exercise	(CPEX)	testing	107 
used	in	selective	cases.	Pre-morbidities	were	optimized	where	possible.	Anemia	was	treated	108 
with	 intravenous	 iron	 transfusion.	 Prior	 to	 surgery,	 patients	 attended	 clinic	 for	 stoma	109 
marking,	 to	 obtain	 6	 carbohydrate	 dinks	 (e.g.	 PreOp	 TM,	 Nutricia)	 and	 to	 collect	 a	 single	110 
injection	of	low	molecular	weight	heparin	(LMWH	e.g.	dalteparin	5,000	iu	s/c).	Patients	self-111 




loading	 for	 the	18	hours	prior	 to	 surgery.	Patients	were	allowed	oral	 fluids	up	 to	2	hours	113 
pre-operatively	and	food	6	hours	pre-operatively.		114 
	115 
Per-operative:	 At	 induction,	 a	 pre-planned	 anaesthetic	 protocol	was	 used	 (supplementary	116 
table	1).	Important	elements	included	limited	fluid	administration	targeted	to	losses,	the	use	117 
of	vasopressors	to	maintain	blood	pressures,	the	avoidance	of	nasogastric	tubes	(NGT)	and	118 
hypothermia	 (e.g.	 using	 Bair	 Hugger	 TM).	 Typically,	 only	 500-1000mls	 intravenous	119 
crystalloid	 was	 administered	 prior	 to	 bladder	 removal.	 Intra-operative	 steps	 taken	 to	120 












include	 the	 seminal	 vesicles.	 In	 females,	 anterior	 pelvic	 exenteration	 included	 the	 uterus,	133 
fallopian	 tubes	 and	 anterior	 vaginal	wall.	 Ovaries	were	 spared,	when	possible	 in	 younger	134 









During	 the	 regimen’s	 introduction,	 an	 ERAS	nurse	 audited	 compliance.	On	 post-operative	141 
day	(POD)	#1	patients	were	allowed	chewing	gum,	one	clear	boiled	sweet/candy	per	hour	142 
and	30mls	 clear	non-fizzy	oral	 fluids	per	hour,	 as	 comfort	 allowed.	 Intake	was	 reduced	 in	143 
patients	feeling	nauseous	or	uncomfortable.	Patients	were	sat	out	of	bed	and	encouraged	to	144 
walk	10-20	meters.	Additional	analgesia	was	allowed	through	on	demand	patient	controlled	145 
analgesic	 (PCA)	 intravenous	 opiates.	 On	 POD#2	 patients	 aimed	 to	 walk	 100	meters	 and	146 
were	 allowed	 to	 drink	 clear	 fluids	 as	 tolerated.	 Nausea	 or	 vomiting	 were	 treated	 with	147 





if	 post-operative	 complications	 were	 apparent.	 Abdominal	 and	 pelvic	 CT	 scan	 was	153 






Primary	 outcomes	 were	 LOS	 and	 post-discharge	 readmission	 rates.	 Secondary	 outcomes	160 




operative	 duration,	 overall	 and	 bladder-cancer	 specific	 survival.	 For	 analysis,	 BMI	 was	162 
stratified	as	underweight	(BMI	<18.5),	healthy	(BMI	18.5–24.9),	overweight	(BMI	25–29.9)	163 
and	 obese	 (BMI	 ≥30)	 [17].	 Pre-operative	 anaemia	was	 defined	 as	 hemoglobin	 <12g/dl	 in	164 
both	sexes	and	renal	impairment	as	estimated	GFR	<40mls/min,	as	per	our	national	registry	165 






453	 consecutive	 patients	 underwent	 radical	 cystectomy	 (table	 2,	 figure	 1).	 The	 median	172 
(IQR)	age	was	70	years	(64-76)	and	14%	of	patients	were	³80	years	old.	Ninety-eight	were	173 
female	(22%)	and	50	(11%)	received	a	neobladder	reconstruction.	Around	one	quarter	of	174 
patients	 had	 renal	 impairment	 (eGFR	 <40mls/min	 in	 107	 (24%))	 prior	 to	 surgery,	 100	175 
(22%)	had	hydronephrosis	or	were	anephric,	the	median	(IQR)	BMI	was	29	(26.0-32.8)	and	176 
177	 (39%)	 had	 Charlson	 Comorbidity	 index	 (CCI)	 of	 4	 or	 higher.	 Twenty-eight	 patients	177 
underwent	robot	assisted	surgery,	of	which	25	had	intracorporeal	reconstruction.	Fifty-nine	178 
patients	 received	 neoadjuvant	 chemotherapy	 (NAC),	 18	 received	 adjuvant	 chemotherapy	179 
and	 29	 palliative	 chemotherapy.	 135	 patients	 had	 invasive	 cancer	 at	 TUR,	were	 younger	180 
than	80	years	of	age,	had	normal	renal	function	and	a	good	performance	status	(CCI	0-3)).	181 
As	such,	the	use	of	NAC	in	these	suitable	cases	was	57/135	(42%)	and	did	not	differ	by	ERAS	182 









to	 surgery	 occurred	 in	 376	 (83%),	 rectus	 sheath	 local	 anaesthetic	 infusions	 used	 in	 241	189 
(53%),	 NGT	 avoided	 in	 382	 (84%),	 pre-operative	 oral	 bowel	 preparation	 avoided	 in	 390	190 
(86%)	and	drains	not	used	 in	20	 (4.4%)	patients.	Carbohydrate	 fluid	 loading	was	used	 in	191 
364	(80%)	and	drinking	until	2	hours	prior	to	anaesthesia	allowed	in	284	(63%).	Patients	192 
with	 ERAS	were	 older	 (median	 (IQR)	 71	 years	 (65-76))	 than	 those	without	 (60	 (61-70),	193 





Length	 of	 stay	 differed	 significantly	 for	 patients	with	 ERAS	 (median	 (IQR)	 8	 (6-13)	days)	199 
and	without	ERAS	 (18	 (13-25))	 recovery	 (supplementary	 figure	1	and	p<0.001).	Over	 the	200 
series,	 LOS	 reduced	 from	 a	 median	 of	 17	 days	 to	 6	 days	 (figure	 1b)	 and	 varied	 with	 a	201 
number	 of	 factors	 (table	 3).	 Longer	 stays	were	 seen	 in	 females	 (12	 days	 vs.	 9	 for	males,	202 
p=0.004),	with	neobladder	reconstruction	 (19	days	vs.	9	 for	 ileal	 conduit,	p=0.001),	 those	203 
with	an	abnormal	BMI	(p=0.001),	in	those	receiving	a	blood	transfusion	(14	days	vs.	10	for	204 
no	transfusion,	p=0.03)	and	in	those	with	comorbidities	(P=0.001)	(see	table	3	for	details).	205 














Readmission	 occurred	 in	 21%	 of	 patients	 (88/417	with	 readmission	 outcomes).	 Twenty-217 
two	patients	(25%)	stayed	1	day	and	24	(27%)	more	than	10	days.	Most	readmissions	were	218 
within	 30	 days	 of	 discharge	 (60/88	 (68%)).	 Patients	with	 ERAS	 had	 fewer	 readmissions	219 
(15%)	 than	 those	 without	 ERAS	 (25%,	 Chi	 sq.	 p=0.04).	 Readmission	 rates	 declined	 over	220 
time	 to	 11%	 for	 the	 last	 100	 cases	 (figure	 1d).	 We	 did	 not	 demonstrate	 differences	 in	221 
readmission	 length	 of	 stay	 by	 ERAS	 use	 (supplementary	 figure	 2).	 ERAS	 use	 was	222 




Intra-operative	 blood	 loss	 (median	 (IQR))	was	 lower	 for	 ERAS	 (600	 (383-969)	mls)	 than	227 
non-ERAS	(1050	(900-1575)	mls)	patients	(Mann-Whitney	U	test	p<0.001).	Consequently,	228 
transfusion	 rates	 were	 lower	 for	 ERAS	 (n=32	 (8.1%))	 than	 for	 non-ERAS	 (n=15	 (25%))	229 
patients	 (Chi	 sq	 p<0.001).	 Blood	 loss	 reduced	 across	 the	 series	 from	 an	 average	 of	 1,237	230 
(first	50	 cases)	 to	557mls	 (last	50	 cases,	 figure	1c).	The	median	 (IQR)	operative	duration	231 
was	 lower	 in	 the	 ERAS	 (2.9	 (2.5-4.0))	 vs	 non-ERAS	 (5.0	 (4.5-6.0))	 (Mann-Whitney	 U	 test	232 
p<0.001,	supplementary	 figure	2).	ERAS	use	was	significantly	associated	with	lower	blood	233 









22)	months	 after	 surgery)	 and	24	 from	other	 causes	 (median	 (IQR)	19	 (6.1-34)	months).	240 
The	 30-day	 mortality	 rate	 was	 1.7%	 (1	 case)	 for	 non-ERAS	 and	 0.3%	 (1	 case)	 for	 ERAS	241 
patients	(Chi	sq.	p=0.14).	There	were	3	(5%)	deaths	 in	 the	non-ERAS	and	8	(2.1%)	 in	the	242 
ERAS	 cohort	 within	 90-day	 of	 cystectomy.	 Of	 the	 90-day	 deaths,	 8/11	 (73%)	 were	 from	243 
metastatic	 BC.	 In	 univariable	 and	 Multivariable	 analysis,	 neither	 30-day	 nor	 90-day	244 
mortality	rates	differed	with	ERAS	use	(Chi	Sq.	and	Logistic	regression	p>0.60).	There	was	245 







[10]).	 The	 ERAS	 Society	 (www.erassociety.org)	 has	 protocols	 within	 several	 surgical	253 
specialities,	 including	 RC.	 Since	many	 RC	 patients	 develop	 complications	 during	 recovery	254 
[4],	 these	 patients	 may	 benefit	 more	 than	 most	 from	 refinements	 in	 post-operative	255 




fewer	 complications,	 a	 faster	 improvement	 in	 return	 of	 quality	 of	 life,	more	 rapid	 bowel	260 




support	 and	 conflict	 with	 the	 field.	 For	 example,	 whilst	 others	 also	 found	 ERAS	 leads	 to	262 
accelerated	 bowel	 recovery	 and	 fewer	 complications,	 many	 report	 shorter	 hospital	 stays	263 
[11,	12,	18].	Within	the	USA,	Daneshmand	et	al.	reported	ERAS	using	110	patients	and	found	264 
its	use	reduced	median	LOS	to	4	days	[12].	With	the	UK,	Arumainayagam	et	al.	found	ERAS	265 
reduced	median	 LOS	 by	 around	4	 days	 [19].	LOS	 can	 reflect	 healthcare	 design	 as	well	 as	266 
rehabilitation.	In	the	UK,	patients	do	not	pay	for	healthcare	and	most	are	discharged	home.	267 
As	 such,	 there	 can	 be	 reluctance	 for	 rapid	 discharge.	 In	 the	 US,	 expensive	 hospital	 stays	268 







elements	 to	 the	 success	 of	 ERAS	 involved	 staff,	 patients	 and	 infrastructure.	 Firstly,	 a	276 
multidisciplinary	 approach	 was	 vital.	 Surgical	 staff	 engaged	 with	 anaesthetic	 staff	 to	277 
plan/anticipate	patient	care,	nursing	staff	were	engaged	in	implementing	ERAS	on	the	ward	278 
and	auditing	pathway	compliance,	whilst	stoma/neobladder	reconstruction	nurses	attended	279 
clinics	 and	 the	ward	 to	 expedite	 competency.	 Unfit	 patients	 or	 those	 at	 increased	 risk	 of	280 
complications	 benefitted	 from	 additional	 surgeon/anaesthetist	 interaction.	 Secondly,	 pro-281 
active	 patient	 engagement	 was	 vital.	 This	 included	 explaining	 anticipated	 recovery	282 
timeframes,	 creating	 an	 ERAS	 booklet	 that	 patient’s	 read	 and	 completed	 during	 their	283 
recovery,	engaging	in	prehabilitation	exercise	regimens	for	the	patient	(and	involving	their	284 
next	of	kin	 in	 these	exercises),	 and	planning	discharge	before	admission	 (e.g.	 stocking	up	285 










There	 are	 important	 limitations	 to	 our	 data.	 Firstly,	 the	 design	 precludes	 a	 meaningful	293 
Multivariable	 analysis	 of	 ERAS	 elements	 as	most	 components	 were	 used	 together	 rather	294 








the	 ERAS	 and	 non-ERAS	 cohort	 are	 imbalanced	 for	 reconstruction	 choice.	 This	 reflects	 a	303 
change	 in	practice	prompted	by	data	suggesting	QOL	 is	similar	 in	many	patients	with	 ileal	304 
conduit	and	neobladder	(unpublished	from	http://www.abdn.ac.uk/urology/research/otis/	305 
and	 [20])	 and	 the	 increased	 use	 of	 RC	 in	 older,	 less	 fit	 patients	 table	 2)	 once	 ERAS	306 
improvements	became	apparent.	We	believe	less	fit	patients	need	the	simplest,	least	morbid	307 















Making	 the	 care	 of	 patient’s	 undergoing	 bladder	 removal	 simpler	 and	 more	 uniform	320 
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Figure	 1.	 The	 use	 of	 ERAS	 following	 radical	 cystectomy.	 ERAS	 Components	 and	396 
outcomes	are	aligned	for	the	453	consecutive	patients.	(a).	Individual	elements	from	the	26	397 
elements	 of	 ERAS	 are	 shown	 for	 each	 patient	 including	 robotic	 assisted	 surgery	 (RARC),	398 
omission	of	a	pelvic	drain,	the	use	of	oral	bowel	preparation,	same	day	admission	to	surgery,	399 
regional	 local	 anaesthesia	 (rectus	 sheath	 blockade),	 epidural	 use,	 nasogastric	 tube	 (NGT),	400 





























































































n % n %
Sex Male 303 77% 52 87%
Female 90 23% 8 13% 0.01
Age Median	(IQR) 71 65-76 66 60.8-70.3 <0.001
Age	>80 Yes 60 15% 2 3.3%
No 333 85% 58 97% 0.01
BMI Underweight	<18.5 2 0.5% 0 0.0%
Healthy	18.5-24.9 96 24% 18 30%
Overweight	25-29.9 105 27% 14 23%
Obese	>30 97 25% 13 22%
Missing 93 24% 15 25% 0.9
Pre-op	Hb	(g/dl) Median	(IQR) 131 120-142 129 118-136.5 0.6
Renal	Function Normal 285 73% 26 43%
eGFR	<40mls/min 102 26% 5 8.3%
Unknown 6 1.5% 29 48% 0.2
Upper	tracts Normal 294 75% 42 70%
Unilateral	hydronephrosis 70 18% 8 13%
Bilateral	hydronephrosis 17 4.3% 0 0.0%
Anephric/solitary 5 1.3% 0 0.0%
Unknown 7 1.8% 10 17% 0.4
Charlson	CI	score 0-3 201 51% 30 50%
4-5 117 30% 13 22%
6-7 16 4.1% 3 5.0%
>8 23 5.9% 5 8.3%
Unknown 36 9.2% 9 15% 0.6
Pre-op	BC	phenotype Low-risk	NMI 5 1.3% 1 1.7%
High-risk	NMI 165 42% 20 33%
Muscle	invasive	BC 223 57% 39 65% 0.4
Reconstruction Ileal	conduit 368 94% 35 58%










Element Number % Median OR p	value OR p	value
Age	(continous) Median	(IQR) 70	(64-76) 100% 10 6 15 0.98 0.95 1.0 0.2
Tumor	phenotype Low-risk	NMI 6 1.3% 7 6 17.5
High-risk	NMI 185 41% 10 7 16
Muscle	invasive	BC 262 58% 10 6 15 2.9 0.5 16.4 0.2
Sex Male 355 78% 9 6 15
Female 98 22% 12 7.8 16 2.2 1.3 3.7 <0.001 3.9 1.9 7.8 <0.001
Robot	assisted Yes 28 6.2% 7 6 10
No 425 94% 10 6 16 2.0 0.9 4.3 0.08
Reconstruction Ileal	conduit 403 89% 9 6 13
Neobladder 50 11% 19 12 25.3 6.4 2.5 16.4 <0.001 5.5 1.3 22.6 0.02
Body	Mass	Index	(continous) Median	(IQR) 29	(26-32) 76% 8 6 16 1.0 0.9 1.0 0.4
Hb	Pre-operation	(g/dl) Anemia 120 26% 7.5 6 14
Normal 175 39% 8 6 12
Missing 158 35% 13 8 19 0.9 0.6 1.5 0.7
Renal	Funtion Normal 311 69% 6 8 14
eGFR	<40mls/min 107 24% 11 7 15
Unknown 35 7.7% 15 12 19 2.1 1.3 3.3 <0.001 1.5 0.8 3.0 0.2
Hydronephrosis None 336 74% 10 6 15
Unilateral 78 17% 10 7 13.3
Bilateral 17 3.8% 12 7 15.5
Anephric/Solitary 5 1.1% 6 5 11.5
Unknown 17 3.8% 15 7.5 21.5 0.2 0.0 1.4 0.1
Charlson	CI 0-3 231 51% 7 6 12
4-5 130 29% 10 7 13
6-7 19 4.2% 12 7 19
>8 28 6.2% 26 22.3 31






Unknown 45 9.9% 15 12 17 32.4 4.3 242.5 <0.001 55.8 6.3 493.0 <0.001
Transfusion Yes 47 12% 14 8 21
No 406 88% 10 6 14 2.2 1.1 4.4 0.03 0.7 0.3 2.2 0.6
"ERAS	Pathway" Yes 393 87% 8 6 13
No 60 13% 18 13 25 45.5 6.2 331.3 <0.001 295 7.5 11649 0.002
Pre-Op	counselling Yes 288 64% 7 6 12
No 165 36% 13 9 20.5 5.8 3.6 9.5 <0.001
Prehabilitation	exercise Yes 239 53% 7 6 12
No 214 47% 12 8 19 3.9 2.6 5.9 <0.001
Mini-Incision Yes 374 83% 8 6 13
No 79 17% 16 12 24 5.3 2.6 10.6 <0.001
NGT	Tube Yes 71 16% 19 13 25
No 382 84% 8 6 13 13.2 4.7 36.8 <0.001
Rectus	sheath	LA No 212 47% 13 8 20
Yes 241 53% 7 6 12 3.8 2.5 5.7 <0.001
Same	day	Admission Yes 376 83% 8 6 13
No 77 17% 16 12.5 23 31.0 7.5 127.9 <0.001
Oral	bowel	preparation Yes 63 14% 16 13 24
No 390 86% 8 6 13 48.1 6.7 352.7 <0.001
Carbohydydrate	loading Yes 364 80% 8 6 12
No 89 20% 16 12 22 14.2 5.7 35.9 <0.001
Fasting	pre-op 2hrs	pre-op 284 63% 7 6 12
6hrs	pre-op 169 37% 13 9.0 20.5 4.9 3.1 7.8 <0.001
Drain Yes 433 96% 10 6.0 15.5
No 20 4.4% 7 5.3 11.5 2.6 1.0 6.4 0.04
Closure Mass	PDS	0 331 73% 11 7.0 17
Sheath	PDS	2/0 122 27% 7 6.0 12 3.0 1.9 4.9 <0.001
Oral	Fluids	from	day	1 Yes 403 89% 9 6.0 13
No 50 11% 19 14.0 25.3 11.3 3.5 37.0 <0.001
Chewing	gum/candy Yes 393 87% 8 6.0 13































































































































































































































































1 51 101 151 201 251 301 351 401
R
e
a
d
m
is
si
o
n
	L
O
S
	(
d
a
y
s)
(a).
(b).
451
451
